Metabolic syndrome, C-reactive protein, and prognosis in patients with established coronary artery disease - 17/08/11
, Marian R. Fisher, PhD b, Christopher M. O'Connor, MD c, Michael W. Dunne, MD d, Joseph B. Muhlestein, MD e, Louis Yao, MD f, Sandeep Gupta, MD g, Rebecca J. Benner, PhD d, Thomas D. Cook, PhD b, Dearborn Edwards, MD d, Marc A. Pfeffer, MD, PhD hfor the Investigators in the Weekly Intervention with Zithromax for Atherosclerosis and its Related Disorder (WIZARD) study
Résumé |
Background |
The prognosis associated with metabolic syndrome and high-sensitivity C-reactive protein (hs-CRP) in patients with stable coronary artery disease has not been well established.
Methods |
The WIZARD study was to determine the effects of 12 weeks of antibiotic therapy on coronary heart disease events in patients with stable coronary artery disease and known Chlamydia pneumoniae exposure. Baseline metabolic risk factors were available for 3319 patients enrolled from 1997 to 1998. The primary outcome was the first occurrence of death, recurrent myocardial infarction, coronary revascularization procedure, or hospitalization for angina.
Results |
Of the 3319 subjects, 825 patients experienced the primary outcome during the mean follow-up of 37 months. For the composite outcome, there was an increased hazard ratio (HR) for metabolic syndrome (HR 1.40, 95% CI 1.22-1.61) (unadjusted) and for hs-CRP (HR 1.60, 95% CI 1.38-1.85) (unadjusted). Both the metabolic syndrome and hs-CRP indicated, in a multivariable model including age and sex, an increased HR for the primary outcome (metabolic syndrome: HR 1.33, 95% CI 1.15-1.53; hs-CRP: HR 1.52, 95% CI 1.30-1.76).
Conclusions |
Although related, the presence of the metabolic syndrome and increased levels of hs-CRP were associated with increased risk of adverse cardiovascular outcomes.
Le texte complet de cet article est disponible en PDF.Plan
| The Weekly Intervention with Zithromax for Atherosclerosis and its Related Disorder (WIZARD) study was supported by Pfizer, of which Drs Dunne, Benner, and Edwards are employees. Drs Pfeffer, O'Connor, and Gupta report having served as a consultant for or having received honoraria and/or research grants from Pfizer. Drs Fisher and Cook received salary support from a contract between the University of Wisconsin and Pfizer. |
Vol 152 - N° 2
P. 298-304 - août 2006 Retour au numéro
Article précédent
- Prospective evaluation of the oxygen uptake efficiency slope as a submaximal predictor of peak oxygen uptake in aged patients with ischemic heart disease
- Christophe Van Laethem, Nico Van De Veire, Johan De Sutter, Jozef Bartunek, Guy De Backer, Marc Goethals, Marc Vanderheyden
- Identification of excess clustering of coronary heart diseases among extended pedigrees in a genealogical population database
- Benjamin D. Horne, Nicola J. Camp, Joseph B. Muhlestein, Lisa A. Cannon-Albright
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?